Table 3.

Ongoing Trials in LS-SCLC Patients

Identifier	Patients	Phase	Intervention Arm	Control Arm	Primary Endpoint
NCT05496166	LS-SCLC N=348	III	Adebrelimab + chemotherapy → surgery→ Adebrelimab	Adebrelimab + chemotherapy→radiotherapy → Adebrelimab	PFS
NCT06483282	LS-SCLC N=38	II	Adebrelimab + Apatinib + Chemotherapy → surgery → Adebrelimab + Apatinib ± radiotherapy	-	EFS
NCT06527898	LS-SCLC N=45	I/II	Chemotherapy + concurrent hypofractionated radiotherapy → Adebrelimab + chemotherapy → Adebrelimab	-	PFS
ChiCTR2400082364	LS-SCLC N=36	II	Hyperfractionated radiotherapy + chemotherapy → adebrelimab maintenance	-	Safety PFS
ChiCTR2500095305	LS-SCLC N=58	IV	Adebrelimab + chemotherapy → Adebrelimab + chemotherapy + radiotherapy	-	PFS
ChiCTR2400086355	LS-SCLC N=38	-	Adebrelimab + chemotherapy → chemotherapy + radiotherapy → Adebrelimab	-	PFS

Abbreviations: LS-SCLC, limited-stage small cell lung cancer; PFS, progression-free survival; EFS, event-free survival.